Urban Paulsson, Chairman of the Board. Urban is a partner at the Lawfirm Nordia. His practise today covers commercial and corporate law matters for Swedish and foreign corporations in the life science industry. During the years 2002-2006 Urban was a partner at Bird & Bird Advokatbyrå where he was heading their Life Science Group in Stockholm. He has built up considerable experience of the Life Sciences industry starting 1994, when he joined the Pharmacia Corporation as a legal counsel and where he focused on transactions involving licensing, acquisitions and divestment. He has also worked as t counsel at Vitrolife AB, a biotech company listed on the Stockholm Stock Exchange. Urban currently serves on the Boards of biotech and life science companies, including Cormorant Pharmaceuticals AB, Sweden (chairman), DermaEffect Sweden AB and Beacon Private Equity AG, Germany. Urban graduated from law school at Lund University in 1988.
William Gunnarsson, Board member. William started his pharmaceutical career with Bristol-Myers where he held positions of increasing responsibility. In 1983 he was appointed the General Manager of the Scandinavian Pharmaceutical Division of the Company. In 1988 he became the President of Nobel Pharma, Ltd., Japan. In 1990 he moved to France where he founded Orphan Europe, a pharmaceutical company specializing in rare and neglected diseases. He served as the Company’s CEO until 2008 when it was successfully sold to Recordati S.p.A., Italy and on whose Board he served until Orphan Europe was fully integrated into Recordati’s operations. William currently serves on the Boards of several biotech companies where he holds important equity positions, including Synphora AB , Premacure AB, Laccure AB, and Prostalund AB all in Sweden. William graduated as an officer from the Royal Swedish Naval Academy in 1969 and earned a degree in economics from the University of Gothenburg, Sweden in 1973.
Göran Smedegård, Ph. D. Board member. Göran has served in positions on increasing respnsiblity with major pharmaceutical companies including Pharmacia and AstraZeneca. He has also experience from the biotech/specialty pharma industry where he served as Vice President Business & Commercial Development at Orexo AB, Sweden. He was the co-founder and served as Senior Investment Manager at Innoventus Centure Capital Fund, Sweden.Göran earned his PhD from the University of Uppsala, Sweden
Fredrik Henell is the CEO of Axcentua Pharmaceuticals. He spent close to 20 years with Pharmacia and predecessor companies, primarily in Business Development roles in Europe (Sweden, Italy and France) and the US. He held similar roles in the US biotech industry (ZymoGenetics) as well as the generic industry (Hospira, Europe). Fredrik received an MBA from the Stockholm School of Economics and an MD and a PhD from the Karolinska Institutet, Stockholm, Sweden.
Anders Berkenstam is the CSO of the Company. He is also a founder and Board member. Following an academic career with publications in peer reviewed scientific journals (Cell, Nature and EMBO Journal) Anders joined Pharmacia in 1996. He subsequently held positions of increasing responsibility in biotech and in pharmaceutical companies. It culminated when he in 2002 became the Vice President of Research & Development at Karo Bio AB, Sweden. During his tenure with the company he successfully shepherded the company’s lead compound into proof-of-concept phase I clinical studies. Anders previously also held a position as Associate Professor at The Methodist Hospital Research Institute, Houston, Texas and is developing novel treatments for neurodegenerative diseases. Anders earned his PhD from the Karolinska Institute, Sweden